This brief summarizes public reporting and official announcements. Research findings may be preliminary. Talk to a qualified clinician before making health decisions.
The FDA approved Bayer’s Sunharbo (asundexian) for use with antiplatelet therapy to reduce stroke risk in adults after a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. It is the first approved factor XIa inhibitor, according to the FDA.
HOW THIS BRIEF WAS MADE 2 outlets: 1 official · 1 specialist. Automated sourcing and summaries by the BLUF engine. Corrections
The approval gives eligible patients and clinicians a new treatment option for reducing stroke risk. The supplied reports do not provide details on how widely it will be used or its cost.
Sunharbo is approved for the patient groups and combination use specified by the FDA. The articles do not report further regulatory steps or launch details.
Availability and pricing of Sunharbo
Further information on its use in the FDA-approved patient groups